Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Up 7.1% in December

Aytu BioPharma, Inc. (NASDAQ:AYTU) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 126,800 shares, an increase of 7.1% from the November 30th total of 118,400 shares. Based on an average daily volume of 37,000 shares, the days-to-cover ratio is currently 3.4 days. Currently, 2.1% of the company’s stock are short sold.

Hedge Funds Weigh In On Aytu BioPharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its position in shares of Aytu BioPharma by 54.5% in the second quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock worth $69,000 after purchasing an additional 8,311 shares in the last quarter. Stonepine Capital Management LLC increased its stake in Aytu BioPharma by 6.0% in the 3rd quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock valued at $1,177,000 after buying an additional 28,489 shares during the period. Finally, Armistice Capital LLC purchased a new stake in Aytu BioPharma in the 2nd quarter worth approximately $736,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Stock Up 5.6 %

Shares of Aytu BioPharma stock traded up $0.09 during midday trading on Tuesday, hitting $1.70. The company’s stock had a trading volume of 18,880 shares, compared to its average volume of 23,966. Aytu BioPharma has a 1-year low of $1.30 and a 1-year high of $3.45. The company has a quick ratio of 0.80, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $10.45 million, a P/E ratio of -1.38 and a beta of -1.40. The stock has a 50-day simple moving average of $1.67 and a 200-day simple moving average of $2.26.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.